Clinical Trial Update: Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase II neoadjuvant trial comparing Gemcitabine plus Nab-Paclitaxel versus modified FOLFIRINOX with SBRT for borderline resectable pancreatic cancer was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Gemcitabine (Gemcitabine)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Nab-paclitaxel (paclitaxel protein-bound)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Nathan Bahary, MD | Conditions: Borderline Resectable Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-06-15